Rituximab with CODOX-M/IVAC
Treatment for Burkitt lymphoma
Effectiveness
88%
Safety Score
25%
Clinical Trials
2
Participants
4K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
0
Rituximab with CODOX-M/IVAC Outcomes
for Burkitt lymphoma
Efficacy Outcomes
Overall Effectiveness
+88%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
2 completed trials for Rituximab with CODOX-M/IVAC in Burkitt lymphoma
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
NCT00392990COMPLETEDPHASE2
25 participants
INTERVENTIONAL
Chicago, United States +7 more
Started: Feb 6, 2007
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
NCT00392834COMPLETEDPHASE2
34 participants
INTERVENTIONAL
La Jolla, United States +12 more
Started: Sep 1, 2006